DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.compose your message
message sent
email sent successfully
Trusted Resources: News & Events
Latest announcements and gatherings
Global Sickle Cell Disease Treatment Market 2019–2023| Evolving Opportunities with ADDMEDICA and Bristol-Myers Squibb | Technavio
The global sickle cell disease treatment market is poised to grow by USD 1.85 billion during 2019-2023, progressing at a CAGR of over 11% during the forecast period.
The market is driven by the high prevalence of sickle cell disease. In addition, the advent of regenerative therapy is anticipated to further boost the growth of the sickle cell disease treatment market.
In the last few years, the sickle cell trait had increased significantly among patients, resulting in the rising number of sickle cell disease cases. It is more prevalent among African-Americans and the number of patients affected by this disease is expected to increase significantly. These factors will increase the demand for sickle cell disease treatment, which will boost market growth during the forecast period.


Related Content
-
education & researchChronic opioid therapy is more strongly associated with central sensitization in sickle cell disease than clinical p...Central nervous system sensitization (CS...
-
news & eventsExperimental Gene Therapy Reverses Sickle Cell Disease for YearsA study of an investigational gene thera...
-
news & eventsPhase 1 trial to test under-the-skin injection of sevuparin in sickle cell patientsModus Therapeutics is going to launch ...
-
education & researchMaternal/Perinatal Outcome in Women With Sickle Cell Disease: A Comparison of Two Time PeriodsObjective: To compare pregnancy outcome...
-
news & eventsDiscovery could help treatments for sickle cell diseaseResearch team establishes biomarkers for...
-
news & eventsEndari reduces pain crises, hospitalizations in sickle cell patients, phase 3 trial showsTreatment with Endari (L-glutamine) le...
-
news & eventsADDMEDICA receives FDA-approval for orphan drug Siklos®, first and sole hydroxyurea-based treatment for paediatric ...ADDMEDICA has announced that the...
send a message
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Support for this site is provided by

This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.